BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 20816019)

  • 1. Dendritic cell vaccination of patients with metastatic colorectal cancer.
    Burgdorf SK
    Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination.
    Burgdorf SK; Claesson MH; Nielsen HJ; Rosenberg J
    Acta Oncol; 2009; 48(8):1157-64. PubMed ID: 19863224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine.
    Burgdorf SK; Fischer A; Myschetzky PS; Munksgaard SB; Zocca MB; Claesson MH; Rosenberg J
    Oncol Rep; 2008 Dec; 20(6):1305-11. PubMed ID: 19020707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study.
    Burgdorf SK; Fischer A; Claesson MH; Kirkin AF; Dzhandzhugazyan KN; Rosenberg J
    J Exp Clin Cancer Res; 2006 Jun; 25(2):201-6. PubMed ID: 16918131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study.
    Ovali E; Dikmen T; Sonmez M; Yilmaz M; Unal A; Dalbasti T; Kuzeyli K; Erturk M; Omay SB
    J Exp Clin Cancer Res; 2007 Jun; 26(2):209-14. PubMed ID: 17725100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reduction of immunosuppression and shift to Th1 response by tumor-DC (dendritic cells) fusion vaccine].
    Iinuma H; Okinaga K; Fukushima R; Inaba T; Iwasaki K; Arai T; Tamura J; Kumagai H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1640-2. PubMed ID: 15553669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
    Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
    Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xenovaccinotherapy for colorectal cancer.
    Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV
    Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.
    Samonigg H; Wilders-Truschnig M; Kuss I; Plot R; Stöger H; Schmid M; Bauernhofer T; Tiran A; Pieber T; Havelec L; Loibner H
    J Immunother; 1999 Nov; 22(6):481-8. PubMed ID: 10570746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.
    Matsumoto A; Haraguchi K; Takahashi T; Azuma T; Kanda Y; Tomita K; Kurokawa M; Ogawa S; Takahashi K; Chiba S; Kitamura T
    Int J Urol; 2007 Apr; 14(4):277-83. PubMed ID: 17470153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
    Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.